Holm, Jeppe Sejerø
Funt, Samuel A. http://orcid.org/0000-0002-7235-6319
Borch, Annie
Munk, Kamilla Kjærgaard
Bjerregaard, Anne-Mette http://orcid.org/0000-0002-1831-6746
Reading, James L. http://orcid.org/0000-0001-5381-978X
Maher, Colleen http://orcid.org/0000-0003-1117-9272
Regazzi, Ashley http://orcid.org/0000-0002-6019-1852
Wong, Phillip http://orcid.org/0000-0002-6360-849X
Al-Ahmadie, Hikmat http://orcid.org/0000-0002-2938-6627
Iyer, Gopa http://orcid.org/0000-0002-5093-6099
Tamhane, Tripti http://orcid.org/0000-0001-6417-3304
Bentzen, Amalie Kai
Herschend, Nana Overgaard
De Wolf, Susan
Snyder, Alexandra
Merghoub, Taha http://orcid.org/0000-0002-1518-5111
Wolchok, Jedd D. http://orcid.org/0000-0001-6718-2222
Nielsen, Morten http://orcid.org/0000-0001-7885-4311
Rosenberg, Jonathan E.
Bajorin, Dean F. http://orcid.org/0000-0003-4001-7088
Hadrup, Sine Reker
Article History
Received: 19 January 2021
Accepted: 7 March 2022
First Online: 11 April 2022
Competing interests
: SAF has received research support from AstraZeneca, Genentech/Roche, is a consultant/advisory board member for Merck, and owns stock in Urogen, Allogene Therapeutics, Neogene Therapeutics, Kronos Bio, and Inconovir. He is also supported by the National Cancer Institute K12CA184746-01A1 grant and the Bochner-Fleisher Research Scholar in Urologic Oncology Award. HAA is a consultant/advisory board member for Bristol Myers Squibb, EMD Serono, AstraZeneca/MedImmune, and Janssen Biotech. GI has a consulting or advisory role for Bayer, Janssen, and Mirati Therapeutics; and has received research funding from Mirati Therapeutics, Novartis, Debiopharm Group, and Bayer. PW is a consultant for Sellas Life Sciences and Leap Therapeutics. AKB and SRH are co-inventors of the licensed patents for DNA Barcoded MHC-multimers (WO2015185067 and WO2015188839), licensee: Immudex, DK. SDW is supported by the MSK Clinical Scholars T32 (5T32CA009512) and Young Investigator Award from the American Society of Clinical Oncology. AS is an employee of and owns stock in Merck and Co. TM is a consultant for Leap Therapeutics, Immunos Therapeutics and Pfizer, and co-founder of Imvaq therapeutics; has equity in Imvaq therapeutics; has received research support from Bristol Myers Squibb, Surface Oncology, Kyn Therapeutics, Infinity Pharmaceuticals, Peregrine Pharmeceuticals, Adaptive Biotechnologies, Leap Therapeutics and Aprea; and is inventor on patent applications related to work on oncolytic viral therapy, alphavirus-based vaccines, neo-antigen modeling, CD40, GITR, OX40, PD-1 and CTLA-4. JDW is a consultant for Amgen, Apricity, Arsenal IO, Ascentage Pharma, AstraZeneca, Astellas, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Dragonfly, F Star, Eli Lilly, Georgiamune, Imvaq, Merck, Polynoma, Psioxus, Recepta, Trieza, Truvax, Sellas, and Werewolf Therapeutics; has equity in Tizona Pharmaceuticals, Imvaq, Beigene, Linneaus, Apricity, Arsenal IO, and Georgiamune; and has received research support from Bristol Myers Squibb and Sephora. JDW is also the co-inventor of the following licensed patents: Xenogeneic DNA Vaccines (USPTO, US7556805), licensee: Merial; Myeloid-derived suppressor cell (MDSC) assay (EPO, PCT/US2013/027475), licensee: Serametrix; Anti-PD1 Antibody (USPTO, US10323091), licensee: Agensus; Anti-CTLA4 antibodies (USPTO, US10144779), licensee: Agensus; Anti-GITR antibodies and methods of use thereof (USPTO, US10155818/US10280226), licensee: Agenus/Incyte. JER holds stock and other ownership interests in Illumina; has received honoraria from AstraZeneca, Bristol-Myers Squibb, Chugai Pharma, Clinical Care Options, Clinical Mind, Intellisphere, Medscape, Peerview, Research To Practice, UpToDate, and Vindico; has a consulting or advisory role for Adicet Bio, Agensys, Astellas Pharma, AstraZeneca/MedImmune, Bayer, BioClin Therapeutics, Bristol-Myers Squibb, EMD Serono, Fortress Biotech, GlaxoSmithKline, Inovio Pharmaceuticals, Janssen Oncology, Lilly, Merck, Pharmacyclics, QED Therapeutics, Roche/Genentech, Seattle Genetics, Sensei Biotherapeutics, and Western Oncolytics; has received institutional research funding from Astellas Pharma, AstraZeneca, Bayer, Genentech/Roche, Incyte, Jounce Therapeutics, Mirati Therapeutics, Novartis, QED Therapeutics, Seattle Genetics, and Viralytics; holds an institutional interest in a patent for a predictor of platinum sensitivity; and has received travel and accommodation expenses from Bristol-Myers Squibb and Genentech/Roche. DFB is a consultant for Bristol Myers Squibb, Merck, Genentech-Roche, Astra-Zeneca, and Pfizer; and has received research support from Merck, Genentech-Roche, Astra-Zeneca, Novartis, and Bristol-Myers Squibb. SRH is the co-founder of Tetramer-shop and PokeACell and co-inventor of the licensed patent for Combination encoding of MHC multimers (EP2088/009356), licensee: Sanquin, NL. The remaining authors declare no conflicts of interest.